• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Tandem Diabetes Care Inc. (Amendment)

    2/13/24 5:15:54 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care
    Get the next $TNDM alert in real time by email
    SC 13G/A 1 tv02035-tandemdiabetescarein.htm SCHEDULE 13G/A tandemdiabetescareinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 7)*

    Name of issuer:  Tandem Diabetes Care Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  875372203

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  875372203

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    23,276

    7.  SOLE DISPOSITIVE POWER

    6,929,983

    8.  SHARED DISPOSITIVE POWER

    91,923

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,021,906

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.77%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Tandem Diabetes Care Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    12400 High Bluff Drive
    San Diego, CA 92130

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    875372203

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $TNDM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNDM

    DatePrice TargetRatingAnalyst
    8/12/2025$10.35Sell → Neutral
    Citigroup
    8/7/2025$14.00Overweight → Neutral
    Piper Sandler
    7/9/2025$14.00Neutral → Sell
    Citigroup
    6/16/2025$24.00Hold
    Truist
    4/10/2025$20.00Neutral
    Mizuho
    3/5/2025$45.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    3/4/2025$35.00 → $24.00Buy → Neutral
    Citigroup
    3/3/2025$38.00 → $22.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $TNDM
    SEC Filings

    View All

    Tandem Diabetes Care Inc. filed SEC Form 8-K: Other Events

    8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

    8/7/25 4:09:32 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Tandem Diabetes Care Inc.

    10-Q - TANDEM DIABETES CARE INC (0001438133) (Filer)

    8/6/25 4:23:50 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

    8/6/25 4:17:35 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has announced a voluntary medical device correction for select t:slim X2 insulin pumps to address a potential speaker-related issue that can trigger an error resulting in a discontinuation of insulin delivery. The error, which appears as a Malfunction 16 alarm to the user, will stop insulin delivery and terminate communication between the insulin pump and the continuous glucose monitoring (CGM) device. If not addressed, this could result in hyperglycemia due to discontinuation of insulin delivery, real-time CGM Estimated Glucose Values, and CGM trends. In severe cases of hyperglycemia, the user may require hospitalization or intervention from a med

    8/7/25 8:30:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2025 and provided full year 2025 guidance. Second Quarter 2025 Highlights Achieved record second quarter sales both in the United States (U.S.) and internationally. Demonstrated year-over-year and sequential gross margin improvement. Initiated an early access program for the t:slim X2™ insulin pump with Control-IQ+ technology integrated with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring sensor in the U.S. Progressed multichannel initiative to include t:slim X2 supplies as a pharmacy benefit beg

    8/6/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Announces Upcoming Conference Participation

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will host meetings and present a company update at the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025 at 1:00pm Eastern Time (10:00am Pacific Time), and Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025 at 9:15am Eastern Time (6:15am Pacific Time). In addition, the Company will host meetings at the Bernstein Insights: Healthcare Leaders and Disruptors 2nd Annual Healthcare Forum on Wednesday, September 24, 2025. The presentations will be webcast live

    7/31/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    November 7, 2023 - FDA Roundup: November 7, 2023

    For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

    11/7/23 3:38:18 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Tandem Diabetes Care upgraded by Citigroup with a new price target

    Citigroup upgraded Tandem Diabetes Care from Sell to Neutral and set a new price target of $10.35

    8/12/25 7:47:28 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Tandem Diabetes Care from Overweight to Neutral and set a new price target of $14.00

    8/7/25 7:35:46 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care downgraded by Citigroup with a new price target

    Citigroup downgraded Tandem Diabetes Care from Neutral to Sell and set a new price target of $14.00

    7/9/25 8:19:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CHIEF COMMERCIAL OFFICER Novara Mark David covered exercise/tax liability with 40 shares and converted options into 76 shares, increasing direct ownership by 0.13% to 28,799 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/19/25 6:14:50 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & Chief Admin. Officer Morrison Susan converted options into 2,600 shares and covered exercise/tax liability with 744 shares, increasing direct ownership by 5% to 39,062 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/19/25 6:14:43 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    PRESIDENT & CEO Sheridan John F converted options into 11,453 shares and covered exercise/tax liability with 5,817 shares, increasing direct ownership by 5% to 111,963 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/19/25 6:14:36 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Leadership Updates

    Live Leadership Updates

    View All

    Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl

    6/20/24 9:00:00 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

    11/7/23 3:47:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline.

    Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' opti

    11/1/23 8:03:30 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Financials

    Live finance-specific insights

    View All

    Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2025 and provided full year 2025 guidance. Second Quarter 2025 Highlights Achieved record second quarter sales both in the United States (U.S.) and internationally. Demonstrated year-over-year and sequential gross margin improvement. Initiated an early access program for the t:slim X2™ insulin pump with Control-IQ+ technology integrated with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring sensor in the U.S. Progressed multichannel initiative to include t:slim X2 supplies as a pharmacy benefit beg

    8/6/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI0d

    7/1/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care Announces First Quarter 2025 Financial Results

    Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights, Financial Results Compared to First Quarter 2024 Achieved record first quarter sales with worldwide growth of 22% Increased pump sales in the United States by 19% on a GAAP basis and 17% on a non-GAAP(1) basis, on strong shipment growth and average selling price improvement Delivered 5 point adjusted EBITDA(1) margin increase Approximately 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi Benefits of Control-IQ Technology were featured for a fourth time i

    4/30/25 4:05:00 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    11/14/24 4:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

    SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

    9/9/24 10:40:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Tandem Diabetes Care Inc.

    SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

    2/14/24 7:37:31 AM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    $TNDM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Sheridan John F bought $102,318 worth of shares (10,000 units at $10.23), increasing direct ownership by 10% to 106,327 units (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 6:15:44 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh bought $149,404 worth of shares (13,720 units at $10.89) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    8/11/25 5:18:51 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

    4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

    3/11/25 6:06:01 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care